ACR issues guidance on reinitiating RMD treatment following COVID-19 recovery
medwireNews: The American College of Rheumatology (ACR) has released recommendations on reinitiating treatment for rheumatic and musculoskeletal diseases (RMDs) following recovery from SARS-CoV-2 infection.
These recommendations form an update to the ACR’s COVID-19 clinical guidance, which says that treatments including immunosuppressants, some conventional DMARDs, biologics (with the exception of those targeting the interleukin-6 pathway), and Janus kinase inhibitors should be temporarily stopped in RMD patients with confirmed or suspected COVID-19.
The guidance on reinitiation states that for uncomplicated COVID-19 – defined as mild or no pneumonia and treated in the outpatient setting or at home – “consideration may be given” to recommencing RMD therapies within 7–14 days of COVID-19 symptom resolution. For asymptomatic patients with a positive SARS-CoV-2 test, the recommendations say that treatments can be restarted 10–17 days after the positive result.
However, for more severe COVID-19, the ACR says that decisions about recommencing RMD therapy “should be made on a case-by-case basis.”
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group
24 July 2020: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.